

EMADOC-1700519818-1976391

European Medicines Agency decision

EMA/PE/0000231892

of 20 March 2025

on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000231892

of 20 March 2025

on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0171/2012 issued on 27 July 2012, the decision P/0166/2014 issued on 8 July 2014, the decision P/0166/2015 issued on 7 August 2015, the decision P/0080/2019 issued on 22 March 2019, the decision P/0388/2019 issued on 4 December 2019 and the decision P/0352/2022 issued on 11 August 2022,

Having regard to the application submitted by Amgen Europe B.V. on 16 October 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2025, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for apremilast (Otezla), are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Amgen Europe B.V., Minervum 7061, 4817 ZK – Breda, Netherlands.

EMADOC-1700519818-1731766
Amsterdam, 31 January 2025

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA/PE/0000231892

Scope of the application

Active substance(s):

Apremilast

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

Pharmaceutical form(s):

Tablet

Oral liquid

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Amgen Europe B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Amgen Europe B.V. submitted to the European Medicines Agency on 16 October 2024 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0171/2012 issued on 27 July 2012, the decision P/0166/2014 issued on 8 July 2014, the decision P/0166/2015 issued on 7 August 2015, the decision P/0080/2019 issued on 22 March 2019, the decision P/0388/2019 issued on 4 December 2019 and the decision P/0352/2022 issued on 11 August 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 25 November 2024.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- tablet, oral liquid, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s);

And to:

- the paediatric population from 1 year to less than 2 years of age;
- tablet, oral liquid, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe;

And to:

- the paediatric population from 2 years to less than 5 years of age;
- tablet, oral liquid, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

2.1.1. Indications(s) targeted by the PIP

Treatment of juvenile psoriatic arthritis (JPsA)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Oral liquid

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of oral liquid for paediatric use
Non-clinical studies	Study 2 (CC-10004-TOX-1125) Toxicity study in mice during the entire developmental phase from weaning to adulthood
Clinical studies	Study 3 <i>This study was deleted as a result of procedure 000715-PIP02-11-M03.</i> Study 4 <i>This study was deleted as a result of procedure 000715-PIP02-11-M03.</i> Study 5 <i>This study was deleted as a result of procedure 000715-PIP02-11-M03.</i> Study 6 (CC-10004-PSA-016 ; PEAPOD) <i>This study was added as a result of procedure 000715-PIP02-11-M03.</i> Double-blind, randomised, placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of apremilast in children from 5 years to less than 18 years of age with active juvenile psoriatic arthritis (JPsA)
Extrapolation, modelling and simulation studies	Study 7 <i>This study was added as a result of procedure 000715-PIP02-11-M03.</i> Extrapolation study to demonstrate/confirm the magnitude of effect of apremilast on efficacy outcomes in children from 5 years to less than 18 years of age with juvenile psoriatic arthritis (JPsA).
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2025
Deferral for one or more studies contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

Authorised indication(s):

- Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

- Invented name(s): Otezla
- Authorised pharmaceutical form(s): Film-coated tablet (tablet)
- Authorised route(s) of administration: Oral use
- Authorised via centralised procedure

2. Treatment of psoriasis

- Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis (PSOR) in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
- Otezla is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years and weighing at least 20 kg who are candidates for systemic therapy.

- Invented name(s): Otezla
- Authorised pharmaceutical form(s): Film-coated tablet (tablet)
- Authorised route(s) of administration: Oral use
- Authorised via centralised procedure

3. Treatment of Behçet's disease

- Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's disease (BD) who are candidates for systemic therapy.

- Invented name(s): Otezla
- Authorised pharmaceutical form(s): Film-coated tablet (tablet)
- Authorised route(s) of administration: Oral use
- Authorised via centralised procedure